Last reviewed · How we verify
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
This is a multicenter, single-arm phase II study to evaluate the efficacy and safety of CS1001 monotherapy for relapsed/refractory classical Hodgkin Lymphoma (rr-cHL)
Details
| Lead sponsor | CStone Pharmaceuticals |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 82 |
| Start date | Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Nov 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hodgkin Lymphoma
Interventions
- CS1001
Countries
China